HUM Stock Analysis — Humana
Sector: Healthcare
AI Verdict
Humana trades at 27.7x next year's earnings while EPS is expected to jump 33.1%, so you're paying up for growth that looks credible given its regulatory and network moat, but any slip could trigger a sharp rerating.
Competitive Moat
Humana specializes in Medicare Advantage plans, leveraging scale, deep provider networks, and data-driven care management to lock in recurring government-backed revenue. Its defensibility comes from regulatory expertise and entrenched relationships with both healthcare providers and the federal government, making it hard for new entrants to replicate its footprint.
Summary
Humana's 33.1% expected EPS growth and 27.7x forward P/E put it in focus as a high-growth outlier among healthcare insurers.
Where It Stands
Humana has returned 37.89% over the past year, trades at 27.7x next year's earnings (well above the healthcare sector median of 22x), and its RSI of 49.8 signals a neutral, non-stretched setup.
Key Metrics
- RSI: 49.8 — Neutral
- Trailing P/E: 36.8x
- Forward P/E: 27.7x
- PEG Ratio: 1.28
- Earnings Growth: +0.3%
- Revenue Growth: +0.2%
- Market Cap: $46.7B
- Dividend Yield: 0.01%
- 1-Year Return: 37.89%
- 52-Week High: $428.88
- 52-Week Low: $163.11
Analyst Consensus
16 Buy · 15 Hold · 2 Sell (33 analysts)
Bull Case
With analysts forecasting 33.1% EPS growth and a forward P/E of 27.7x, you're paying a fair price for unusually rapid earnings expansion in a defensive sector.
Bear Case
If Humana's forward P/E compresses to the sector median of 22x, the stock could lose about 20%, even before factoring in any earnings disappointment.
Catalyst to Watch
Watch for Medicare Advantage enrollment updates—if growth exceeds expectations, the high forward multiple looks justified.